NEW YORK, November 30, 2016 /PRNewswire/ --
The Biotech arena might have experienced double-digit declines earlier this year, but following Trump's victory in the presidential election, fund managers are now predicting an uptick in M&A activities within the industry, which should present some investment opportunities. However, uncertainties still linger on worries of Trump's intention to repeal elements of Obamacare. Ahead of today's trading session, Stock-Callers.com turns to four stocks to see how they are currently faring: Biogen Inc. (NASDAQ: BIIB), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Seattle Genetics Inc. (NASDAQ: SGEN), and Grifols S.A. (NASDAQ: GRFS). These stocks research reports can be downloaded now by simply registering for free at:
On Tuesday, shares in Cambridge, Massachusetts headquartered Biogen Inc. recorded a trading volume of 1.39 million shares. The stock ended the session 0.33% lower at $302.77. The Company's shares have gained 6.74% in the last one month. The stock is trading 7.85% above its 200-day moving average. Moreover, shares of Biogen, which discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders, have a Relative Strength Index (RSI) of 45.77.
On November 8th, 2016, research firm Mizuho initiated a 'Buy' rating on the Company's stock, issuing a target price of $290 per share.
On November 18th, 2016, Eisai Co., Ltd announced that the U.S. FDA has granted Fast Track designation for the development of the beta secretase cleaving enzyme (BACE) inhibitor E2609 which was discovered by Eisai and is being jointly developed by Eisai and Biogen. E2609 is currently being investigated in Phase III clinical studies for early Alzheimer's disease. E2609 is an investigational next-generation oral candidate for the treatment of Alzheimer's disease that is believed to inhibit BACE, a key enzyme in the production of amyloid beta. Your complete research report on BIIB can be retrieved for free at:
San Rafael, California headquartered BioMarin Pharmaceutical Inc.'s stock closed the day 1.88% lower at $86.70, with a total trading volume of 1.12 million shares. The Company's shares have advanced 6.87% in the past month. The stock is trading 1.25% below its 200-day moving average. Additionally, shares of BioMarin Pharma, which develops and commercializes pharmaceuticals for serious diseases and medical conditions in the US, Europe, Latin America, and internationally, have an RSI of 47.27.
On October 27th, 2016, BioMarin Pharmaceutical's GAAP net loss for Q3 2016 was $43 million, or $(0.26) per basic and diluted share, compared to GAAP net loss of $91 million, or $(0.57) and $(0.60) per basic and diluted share, respectively, for Q3 2015. BioMarin's total revenues for Q3 2016 were $280 million, an increase of 34% compared to the same period in 2015. The company's Vimizim's net product revenues increased to $81 million, a 25% y-o-y surge.
On November 7th, 2016, research firm Piper Jaffray downgraded the Company's stock rating from 'Overweight' to 'Neutral'. BMRN free report is just a click away at:
Shares in Bothell, Washington headquartered Seattle Genetics Inc. recorded a trading volume of 1.79 million shares, which was higher than their three months average volume of 1.10 million shares. The stock ended yesterday's trading session 0.91% lower at $66.38. The Company's shares have advanced 30.54% in the past month, 46.47% in the previous three months, and 47.91% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 14.05% and 49.73%, respectively. Furthermore, shares of Seattle Genetics, which develops and commercializes targeted therapies for the treatment of cancer worldwide, have an RSI of 54.11.
On November 10th, 2016, Seattle Genetics announced that the U.S. FDA has granted Breakthrough Therapy Designation to ADCETRIS (brentuximab vedotin) for the treatment of patients with CD30-expressing mycosis fungoides and primary cutaneous anaplastic large cell lymphoma (pcALCL) who require systemic therapy and have received one prior systemic therapy. ADCETRIS has been evaluated in CD30-expressing cutaneous T-cell lymphoma in investigator- and corporate-sponsored clinical trials. Sign up for your complimentary research report on SGEN at:
Barcelona, Spain headquartered Grifols S.A.'s stock finished Tuesday's session 0.64% higher at $15.74 with a total trading volume of 736,384 shares. The Company's shares have advanced 8.55% in the last one month. The stock is trading above its 50-day moving average by 1.92%. Additionally, shares of Grifols, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the US, Canada, and internationally, have an RSI of 56.91.
On October 20th, 2016, Grifols announced that it has expanded the menu of tests offered at the Grifols Immunohematology Center laboratory to include basic and advanced serological and molecular testing. The Grifols Immunohematology Center, offers extensive testing capabilities, expert consulting, and classroom and laboratory-based educational programs for transfusion medicine professionals. Register for free on Stock-Callers.com and download the latest research report on GRFS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA